tiprankstipranks
Aligos Therapeutics (ALGS)
NASDAQ:ALGS
US Market
ALGS
Aligos Therapeutics
RESEARCH TOOLSreports
Want to see ALGS full AI Analyst Report?

Aligos Therapeutics (ALGS) Stock News & Sentiment

296 Followers
Aligos Therapeutics Licenses Hepatitis B Drug Rights to Amoytop
Premium
Company Announcements
Aligos Therapeutics Licenses Hepatitis B Drug Rights to Amoytop
15d ago
8K
ALGS
Aligos Therapeutics: Data-Driven Phase 2 Update Supports Buy Rating and $50 Target on Pevifoscorvir’s HBV Opportunity
Premium
Ratings
Aligos Therapeutics: Data-Driven Phase 2 Update Supports Buy Rating and $50 Target on Pevifoscorvir’s HBV Opportunity
21d ago
ALGS
Aligos Advances HBV Candidate With Interim Data, Fast Track
Premium
Company Announcements
Aligos Advances HBV Candidate With Interim Data, Fast Track
22d ago
8K
ALGS
ALGS Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
ALGS Earnings this Week: How Will it Perform?
2M ago
ALGS
Aligos Advances Hepatitis B Candidate With New Renal Safety Study, Keeping Long-Term Upside in Play
Premium
Company Announcements
Aligos Advances Hepatitis B Candidate With New Renal Safety Study, Keeping Long-Term Upside in Play
2M ago
ALGS
Aligos Therapeutics Appoints New Principal Accounting Officer
Premium
Company Announcements
Aligos Therapeutics Appoints New Principal Accounting Officer
3M ago
8K
ALGS
Aligos’ New Phase 1 Hepatitis B Study Signals Steady Progress in High-Need Market
Premium
Company Announcements
Aligos’ New Phase 1 Hepatitis B Study Signals Steady Progress in High-Need Market
4M ago
ALGS
More ALGS News >

ALGS News on the Web

Aligos Inks $25M Upfront Licensing Deal for HBV Therapy in Greater China—Potential Milestones Reach $420M
Market Chameleon
Neutral
Aligos Therapeutics signs license deal to develop pevifoscorvir in China
TipRanks News
Bullish
Piper Sandler Remains a Buy on Aligos Therapeutics (ALGS)
TipRanks News
Bullish
Aligos Secures $25M Upfront and Up to $420M Potential Milestones in Exclusive Greater China Deal for Pevifoscorvir Sodium
Market Chameleon
Bullish
Aligos Interim Analysis Supports HBV Program, Fast Track Granted
rttnews
Bullish
Aligos Therapeutics: Data-Driven Phase 2 Update Supports Buy Rating and $50 Target on Pevifoscorvir’s HBV Opportunity
TipRanks News
Bullish
Aligos Advances HBV Candidate With Interim Data, Fast Track
TipRanks News
Neutral
Aligos reports first interim analysis of B-SUPREME study, fast track designation
TipRanks News
Neutral

News Score - Last 7 Days

Very Positive
ALGS
Sector Average
Media Buzz
This Week8 articles
Weekly Average2.25 articles
News Sentiment
This Week100%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ALGS’s Media Buzz Sentiment?
8 articles about ALGS were published this week. In an average week, 2.25 articles are published.
    What is ALGS’s weekly average amount of articles?
    In an average week, 2.25 articles about ALGS are published.
      What is ALGS’s News Sentiment?
      100% of articles about ALGS were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        TVTXTravere Therapeutics
        HVOOpen Orphan Plc
        PBMPsyence Biomedical
        QDELQuidelOrtho
        Showing the stocks with the most bullish news sentiment over the past week